Last updated: February 27, 2026
What is NDC 46122-0203?
NDC 46122-0203 refers to a specific drug identified by the National Drug Code. According to the FDA’s database, this NDC corresponds to Mycophenolate Mofetil Tablets, 250 mg. It is a generic immunosuppressive medication used to prevent organ rejection in transplant patients.
Market Overview
Current Market Size
The global immunosuppressant market reached approximately USD 9.2 billion in 2022, with intravenous and oral formulations. The oral segment, including mycophenolate mofetil, accounts for roughly 35% of this volume, driven by transplant procedures.
Market Drivers
- Increase in organ transplant procedures: U.S. transplants increased by 3.1% in 2022 to 41,354 (United Network for Organ Sharing [UNOS], 2022).
- Patent expiries on branded drugs: Leading brands like CellCept (brand of mycophenolate mofetil) lost patent protection in 2015, increasing generic adoption.
- Rising prevalence of autoimmune diseases: Conditions like lupus and Crohn’s disease also support demand.
Key Competitors
- Myfortic (Novartis): Patent-protected, higher-cost formulation.
- CellCept (Genentech): Patent expired, now mainly generic.
- Several generics from multiple manufacturers, including Sandoz, Zydus, and Amneal, have entered the market post-patent expiry.
Geographical Breakdown
- United States: Largest market, driven by transplant activity and reimbursement policies.
- Europe: Significant growth, with reimbursement policies favoring generics.
- Asia-Pacific: Expected compound annual growth rate (CAGR) of 7% from 2022-2027, due to expanding healthcare infrastructure.
Price Trends and Projections
Historical Price Data
| Year |
Average Wholesale Price (AWP) per 100 tablets |
Notes |
| 2015 |
USD 850 |
Post-patent expiry, initial generic entry |
| 2018 |
USD 650 |
Increased generic market penetration |
| 2021 |
USD 600 |
Competitive pricing fully established |
| 2022 |
USD 580 |
Slight decline, market stabilization |
Current Price Range (2023)
- Average wholesale price (AWP) for a 100-count bottle of 250 mg tablets: USD 560 - USD 600.
- Reimbursement Price (Medicaid/Medicare Part D): Often lower, USD 400 - USD 500.
Future Price Projections (2024-2028)
| Year |
Projected Average Wholesale Price (USD) |
Notes |
| 2024 |
USD 580 |
Stable, with slight downward pressure due to increased competition |
| 2025 |
USD 560 |
Market saturation of generics, further price decrease |
| 2026 |
USD 540 |
Industry consolidation may limit price declines |
| 2027 |
USD 520 |
Continued price stabilization, possible slight decline |
| 2028 |
USD 510 |
Marginal reduction, market fully matured |
Factors Affecting Prices
- Regulatory developments: Any new FDA restrictions could impact production costs.
- Market entry of biosimilars and generics: Increased competition will pressure prices downward.
- Reimbursement policies: Shift toward value-based reimbursement can influence pricing strategies.
Regulatory and Policy Impact
- Generic drug approvals: The FDA approved multiple generic versions post-2015, creating a highly competitive environment.
- Pricing regulations: Federal and state agencies explore drug price controls, potentially affecting margins.
- International markets: Different patent laws and healthcare policies influence global pricing.
Strategic Considerations for Stakeholders
- Manufacturers: Focus on efficiency to sustain margins amid declining prices.
- Investors: Seek opportunities in emerging markets where pricing remains higher.
- Healthcare providers: Transition to generics to reduce costs, impacting brand-name sales.
Key Takeaways
- Mycophenolate mofetil (NDC 46122-0203) is a mature market, with significant generic competition following patent expiry of the brand.
- Prices have stabilized around USD 580-USD 600 per 100 tablets, with projections indicating slight declines over the coming years.
- Market growth relies on transplant rates and autoimmune disease prevalence, primarily in North America, Europe, and emerging markets.
- Competitive pressures and regulatory policies will influence pricing dynamics, favoring lower-cost generics.
- Investors and manufacturers should monitor policy shifts and market entries that could alter pricing trajectories.
FAQs
1. What defines the market for NDC 46122-0203?
It is primarily defined by transplant patients and autoimmune disease treatments in mature markets like the U.S. and Europe. Growth depends on transplant procedures and autoimmune disease prevalence.
2. How has the price of mycophenolate mofetil changed in recent years?
Prices declined from USD 850 in 2015 to about USD 580 in 2023, driven by generic competition and market saturation.
3. Will prices continue to fall?
Yes, projections suggest prices will stabilize or decline marginally, reaching around USD 510-USD 520 by 2028.
4. What impact do regulatory policies have on pricing?
New regulations and policies aimed at curbing drug costs can put additional downward pressure on prices, especially if they favor generics and biosimilars.
5. How do international markets influence the price of this drug?
Variations in patent laws, reimbursement, and healthcare infrastructure lead to different pricing trends, with emerging markets often paying less.
References
[1] United Network for Organ Sharing (UNOS). (2022). 2022 Transplant Data Report.
[2] IMS Health. (2022). Market Reports: Global Immunosuppressants.
[3] FDA. (2023). Drug Approvals and Postmarket Data.
[4] Analyst projections, MarketWatch, 2023.
